Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06331910
Other study ID # TITNCUES
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date April 1, 2024
Est. completion date May 1, 2025

Study information

Verified date March 2024
Source Assiut University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate Safety and efficacy of topical insulin in treatment of neurotrophic corneal ulcers


Description:

Neurotrophic keratopathy is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation. A reduction In corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing epithelial keratopathy, ulceration and perforation. Because decreased corneal sensitivity is the hallmark sign of neurotrophic keratitis (NK), corneal sensitivity testing should be performed as soon as It is suspected There are 2 common ways to test-one qualitative, the other quantitative: The qualitative method is most commonly used In clinic and often achieved with a cotton tipped applicator because It is easily accessible. The most common quantitative method is the handheld esthesiometer (Cochet-Bonnet). Standard treatment of neurotrophic corneal ulcer involves aggressive lubrication of the corneal surface, therapeutic contact lenses, amniotic membrane grafts and tarsorrhaphy . Refractory neurotrophic corneal ulcers occur when treatment response is incomplete and are potentially blinding. Insulin is a widely available, relatively safe, and familiar medication that has been shown to improve corneal epithelial healing In vitro and in diabetic animal models. However, clinical experience with topical insulin in patients with non-healing corneal wounds is minimal. Insulin-like growth factor-1 (IGF-1) has been shown to be an important modulator of corneal wound healing. Topical insulin may be a simple and effective treatment for neurotrophic corneal ulcers. The main outcome measurements for improvement are the decrease of ulcer size by fluroscien stain,the increase in visual acuity.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 14
Est. completion date May 1, 2025
Est. primary completion date April 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patients with neurotrophic corneal ulcers caused by: - Herpes simplex or Herpes zoster viral infection - Topical anesthetics abuse - Chemical and physical burn - Chronic CL wear - Following LASIK,PRK,CXL - Following vitrectomy and endophotocoagulation for retinal detachment - Diabetes mellitus - Leprosy - Trigeminal neuralgia surgery Exclusion Criteria: - Non compliant patients with the study protocol

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
insulin eye drops
Insulin eye drops deliver insulin directly to the cornea, They exploit insulin's ability to stimulate cell growth, potentially reducing healing time with minimal side effects.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

References & Publications (4)

Nishida T, Yanai R. Advances in treatment for neurotrophic keratopathy. Curr Opin Ophthalmol. 2009 Jul;20(4):276-81. doi: 10.1097/icu.0b013e32832b758f. — View Citation

Shanley LJ, McCaig CD, Forrester JV, Zhao M. Insulin, not leptin, promotes in vitro cell migration to heal monolayer wounds in human corneal epithelium. Invest Ophthalmol Vis Sci. 2004 Apr;45(4):1088-94. doi: 10.1167/iovs.03-1064. — View Citation

Wang AL, Weinlander E, Metcalf BM, Barney NP, Gamm DM, Nehls SM, Struck MC. Use of Topical Insulin to Treat Refractory Neurotrophic Corneal Ulcers. Cornea. 2017 Nov;36(11):1426-1428. doi: 10.1097/ICO.0000000000001297. — View Citation

Zagon IS, Klocek MS, Sassani JW, McLaughlin PJ. Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch Ophthalmol. 2007 Aug;125(8):1082-8. doi: 10.1001/archopht.125.8.1082. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Decrease in ulcer size and the increase in visual acuity . To evaluate the effect of topical insulin eye drops in treatment of neurotrophic corneal ulcer. baseline
See also
  Status Clinical Trial Phase
Terminated NCT02600429 - Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 Phase 3
Recruiting NCT04604834 - Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy N/A
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Completed NCT04293549 - An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops
Completed NCT04957758 - Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy Phase 2
Terminated NCT03084861 - A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy Phase 1/Phase 2
Active, not recruiting NCT06411145 - Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis Phase 4
Recruiting NCT05555589 - Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 Phase 3